​​With current treatments, focal segmental glomerulosclerosis (FSGS), the largest cause of nephrotic syndrome, frequently progresses to end-stage kidney disease. Gebeshuber et al. (2023) assembled 376 FSGS-associated proteins into a FSGS pathophysiology model, major components of which were Reactome pathways for signal transduction and hemostasis. The 39 proteins shared between FSGS model and a 102-protein model for the antiplatelet drug clopidogrel included 20 therapeutic targets of the drug. Tested in an FSGS mouse model, clopidogrel significantly attenuated disease severity, repositioning the drug as an attractive candidate for human clinical trials for FSGS.